Rock Creek Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rock Creek Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$243K	–	134
2019 Q4	$243K	Sell	15,000 -3,500	-19%	-$54.3K	0.1%	110
2019 Q3	$241K	Buy	18,500 +3,500	+23%	+$42.8K	0.11%	96
2019 Q2	$195K	Buy	+15,000	New	+$189K	0.09%	102

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Rock Creek Group's RVNC Position: Q1 2020 in Review

Rock Creek Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2020, closing a stake of 15,000 shares — an estimated $243K sold.

Rock Creek Group first reported a position in RVNC in Q2 2019 and held it in 3 quarters. The position peaked at $243K in Q4 2019. 130 funds tracked by Wall St. Rank hold RVNC as of Q1 2020.

Rock Creek Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Rock Creek Group sold 15,000 Revance Therapeutics, Inc. shares in Q1 2020, an estimated $243K.
Rock Creek Group first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
Rock Creek Group's Revance Therapeutics, Inc. position peaked at $243K in Q4 2019.
130 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2020.

Based on Rock Creek Group's 13F filing for Q1 2020, filed 15 May 2020.